Mucormycosis, a fungal infection caused by Mucorales, has high mortality rates in people with weakened immune systems and ...

Mucormycosis, a fungal infection caused by fungi from the order Mucorales, can cause severe disease, especially in ...

Their paper, “A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response,” was recently accepted and published in the Science Translational Medicine journal.

Summary: Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the Cε3 domain of immunoglobulin E (IgE) and forms complexes that inhibit the immune system's response to ...

Many challenges will have to be faced in the next decade to bring more efficient and affordable antibody-based drugs to the clinic. Here, we discuss strategies to select the best therapeutic ...

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...

Mucormycosis, a life-threatening fungal infection with high mortality rates, has seen a glimmer of hope through research by ...

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra | ...

Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...

For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard therapy is more efficacious for providing a complete renal response than ...